JPMorgan Chase & Co. Increases Stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

JPMorgan Chase & Co. boosted its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 49.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 122,968 shares of the life sciences company’s stock after buying an additional 40,604 shares during the period. JPMorgan Chase & Co. owned approximately 0.16% of Integra LifeSciences Holdings Corporation worth $5,180,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Manhattan Co. purchased a new position in Integra LifeSciences Holdings Corporation during the first quarter worth $117,000. Ladenburg Thalmann Financial Services Inc. increased its position in Integra LifeSciences Holdings Corporation by 77.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,697 shares of the life sciences company’s stock worth $100,000 after buying an additional 742 shares in the last quarter. LS Investment Advisors LLC increased its position in Integra LifeSciences Holdings Corporation by 90.7% in the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock worth $102,000 after buying an additional 1,147 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Integra LifeSciences Holdings Corporation by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock worth $107,000 after buying an additional 1,751 shares in the last quarter. Finally, Elkfork Partners LLC increased its position in Integra LifeSciences Holdings Corporation by 121.2% in the first quarter. Elkfork Partners LLC now owns 3,212 shares of the life sciences company’s stock worth $135,000 after buying an additional 1,760 shares in the last quarter. 89.71% of the stock is currently owned by institutional investors.

Integra LifeSciences Holdings Corporation (IART) traded down 0.32% during mid-day trading on Friday, hitting $49.95. The company had a trading volume of 881,971 shares. The company has a 50-day moving average price of $53.65 and a 200 day moving average price of $46.50. The firm has a market capitalization of $3.90 billion, a P/E ratio of 60.91 and a beta of 0.75. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same quarter in the previous year, the business earned $0.40 EPS. Integra LifeSciences Holdings Corporation’s revenue for the quarter was up 13.2% compared to the same quarter last year. Equities analysts forecast that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/07/30/integra-lifesciences-holdings-corporation-nasdaqiart-shares-bought-by-jpmorgan-chase-co-updated-updated-updated.html.

A number of research firms have weighed in on IART. UBS AG reissued a “buy” rating and issued a $60.00 target price (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Zacks Investment Research upgraded Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research report on Thursday. Oppenheimer Holdings, Inc. set a $60.00 price target on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $65.00 price target on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Wednesday. Finally, Raymond James Financial, Inc. upped their price target on Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation has an average rating of “Buy” and a consensus target price of $52.63.

In related news, Director James M. Sullivan sold 15,658 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $45.89, for a total value of $718,545.62. Following the completion of the transaction, the director now owns 70,154 shares in the company, valued at approximately $3,219,367.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Glenn Coleman sold 13,865 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $45.91, for a total value of $636,542.15. Following the completion of the transaction, the vice president now owns 18,519 shares of the company’s stock, valued at approximately $850,207.29. The disclosure for this sale can be found here. In the last 90 days, insiders sold 304,523 shares of company stock valued at $14,812,988. 21.50% of the stock is owned by company insiders.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply